Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Binaotong is a botanical nasal spray developed by Beijing Qifu Ruicao Medical Technology for the acute treatment of migraine, specifically those characterized by Blood Stasis Syndrome in Traditional Chinese Medicine (TCM). Positioned as a fast-acting analgesic, the drug is administered intranasally to provide rapid relief of migraine symptoms by leveraging the high vascularity of the nasal mucosa for direct absorption. It has undergone Phase II clinical trials in China to determine optimal dosing regimens and evaluate its safety and efficacy profile. As a Class 6.1 New Chinese Medicine, it represents a standardized herbal formulation designed for acute pain management in migraine patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Binaotong.